Sichuan was the first to announce 25 varieties of payment standards for the collection of non-selected pharmaceutical enterprises to bring five practical effects.

On September 24, the Sichuan Medical Insurance Bureau issued a public consultation on the issuance of a notice (draft for comments) on the issuance of the national organization's centralized procurement and use of drugs to expand the relevant drug medical insurance payment standards.
In the annex section, Sichuan Province announced the national organization of drug centralized procurement and use of the pilot expansion of the relevant drug health insurance payment standards, around 25 drugs, Sichuan for different pharmaceutical companies, different product regulations of 503 drugs set payment standards.
, Sichuan stated in the circular that the payment criteria applied to the centralized procurement and use of the pilot expansion of 25 drugs by national organizations, including selected and non-selected drugs.
, whether it is a selected or non-selected variety, you need to refer to this standard for medical insurance reimbursement.
is Sichuan? We believe that, first, because of the large number of insured people in Sichuan Province, for the pilot of the province's unified standards of health insurance payment, many people appear to have weight.
2 is because the national level of the southwest region health care reform linkage has great expectations, such as the southwest five provinces cross-regional outpatient off-the-go settlement, such as long-term care insurance pilot here have a lot of forward-looking, in-depth pilot.
Three is because from a central and western province with a basic representative, from the provincial health insurance payment standards to the national provinces are reference to the development of provincial health insurance payment standards, Sichuan Province is basically in the middle of the belt, can radiate to other regions.
this article, we discuss some of the practical effects of this new policy in Sichuan, especially on the collection of non-selected pharmaceutical companies.
Sichuan Province took the lead in formulating provincial health insurance payment standards, we believe that the main impact has five aspects: First, Sichuan's first batch of 25 varieties collected by the state to develop payment standards, showing a stable foundation and broad prospects.
These 25 varieties were collected by the state relatively early and have an advantage in time;
is that the medical insurance department to develop a unified standard of medical insurance payment, for pharmaceutical companies to lose a piece of the game hinterland.
Whether or not the varieties of pharmaceutical enterprises are included in the scope of national collection, provincial and municipal procurement, regardless of whether pharmaceutical enterprises to participate in the collection of competition enthusiasm or indifference, the unified standard of payment of medical insurance is there.
you reject it is to give up the health care market, pharmaceutical companies only go in the same way.
is that the medical insurance drug catalog is no longer all pharmaceutical companies to squeeze the head to enter, after entering is no longer a safe nest.
Because the State Health Insurance Administration and other nine departments issued "on the national organization of drug centralized procurement and use of pilot expansion of regional scope of implementation opinion" has clearly stated that the same generic name of the drug in principle applicable to the same payment standards, early into the late, into the north and south wind.
, the State Health Insurance Administration and other nine departments issued "on the national organization of drug centralized procurement and use of the pilot expansion of regional scope of implementation of the opinion" clearly pointed out that the exploration of centralized procurement of pharmaceutical medical insurance payment standards and procurement price synergy.
" For centralizedly procured drugs, the medical insurance fund shall, in principle, settle the original research drugs under the same generic name, the evaluation of generic drugs, and generic drugs evaluated by consistency, with the centralized purchase price as the standard of payment for medical insurance within the scope of the medical insurance catalogue.
Patients use drugs higher than the payment standard, the part of the payment standard is paid by the patient, such as the patient's drug price and the selected drug centralized purchase price difference is large, can gradually adjust the payment standard, adjust in place within 2-3 years, and formulate supporting policy measures;
on the basis of ensuring quality and supply, medical institutions and patients to form reasonable drug habits.
a fixed-point retail pharmacy participating in the purchase may be allowed to increase the price appropriately on the basis of the selected price, the part that exceeds the payment standard shall be paid by the patient, and the following part of the payment standard shall be reimbursed by the medical insurance in accordance with the provisions".
fourth is in deepening medical reform, to collect as the representative of the recruitment, as well as to pay standards as the representative of the payment reform.
The influence between the two is gradually transformed, collecting tools are good at finding prices through market competition, in the actual operation of fish leakage, payment standards are longer than system protection, both to adjust the pharmaceutical industry, protect health insurance funds, patients' consumer rights and interests.
friday is the predictable increase in coverage, research and transparency of Medicare payment standards.
the development of payment standards itself is a very controversial thing, between pharmaceutical companies, public opinion supervision from one to the next.
but as long as the determination is greater than worry, you can immediately find a lot of reference systems, such as industry data, business advice, academic research and so on.
payment standards are accepted by society.
for the collection of non-selected enterprises, we think that basically only these options are left: First, Mo fist rub, waiting for the next collection in the full fight for the election.
This is not impossible, there is a saying called "first fat is not fat", do not look at the national drug collection has been carried out three batches, the first three batches of selected enterprises are not all clear strategic support "win", these pharmaceutical companies also have arguments within.
And the current unelested pharmaceutical companies in the unelested track suffered a new blow, may also be a further change of mentality, but also want to hold a ticket in the left hand, the right hand with the end of the hospital promotion, two-pronged, stay in the market do not do change.
is the Mingshing Road, seize the health insurance, non-medical insurance, international B2B market.
not the chinese drug companies can immediately reduce the price of the affected areas of the internet, this is not the first to eat crabs, there have been previous examples.
If at the same time outside Sichuan to open a sharp reduction in the price of hanging the internet, will undoubtedly be on the list of industry hot search, but also become a health care reform policy, landing supervision department's heart is good, in the domestic health insurance, non-medical insurance market will be a "cut" to become famous.
again, not the drug companies can consider going out to sea, once to the high seas on a calmer.
third is broken cans, simply be merged, transferred, by the second venture.
In the new era of mass entrepreneurship and innovation, even the health care policy department, the comprehensive medical reform department can not sit still, for the sale of gold, drug prices can be said to be frequent knife, knife blood, aggressive, the old road has been broken.
part of the most open, but also the most failed pharmaceutical companies can imitate the health hall, farmer mountain spring, since the medicine can not touch, simply do health care products, do the concept of quick-kill.
there is the equivalent of Science and Technology, net red plate, on the courage to eat.
the provincial level to set the standard of health care payment, not too soon, but too late, has reached the point where the arrow in the string, had to be sent.
relevant policy research has long been laid out, Sichuan New Deal is only the tip of the iceberg, the vast number of pharmaceutical companies only see the trick, and early plans.
original title: Quanming Sichuan announced 25 varieties of payment standards, is the late autumn of 2020 to give pharmaceutical companies the first cup of milk tea.